The Drug Revolving Fund (DRF) scheme is a self-sustaining financing mechanism designed to guarantee continuous availability of essential medicines in public health facilities. In many Nigerian health institutions, erratic drug supplies historically crippled patient care. When a facility runs out of medicines, patients are forced to purchase them from expensive private out-of-pocket pharmacies. The DRF solves this by using initial seed capital—often provided by government or donor agencies—to procure an initial stock of essential drugs.
Once patients buy these medications at affordable, subsidized prices, the cash generated is pooled back into the system to repurchase fresh stock. The fund thus 'revolves,' theoretically preventing stockouts without requiring constant fresh injections of government capital.
For a DRF scheme to survive the economic realities of public healthcare delivery, specific operational guidelines must govern its day-to-day administration.
The operational cycle of a DRF moves through distinct phases: quantification, procurement, warehousing, dispensing, and revenue collection. Quantification involves estimating the exact quantities of drugs needed based on past consumption rates and disease patterns. Poor quantification leads either to dead stock that expires on the shelf or frustrating stockouts.
Procurement should target trusted manufacturers or accredited central medical stores to guarantee quality and secure competitive bulk pricing. Once supplies arrive, strict inventory control techniques—such as the First-Expired, First-Out (FEFO) principle—must govern shelf organization to minimize financial losses from expired medications.
Cost recovery is the cornerstone of sustainability for any revolving fund. However, several financial pitfalls threaten this balance. Credit sales represent the single greatest threat to a DRF. When healthcare facilities issue drugs on credit to staff or emergency patients without strict recovery mechanisms, cash flow seizes up, and the fund cannot restock.
Furthermore, inflation poses a constant danger. If local currency depreciates or wholesale prices surge, the cash recovered from selling a batch of drugs may no longer be enough to buy the exact same quantity of replacement stock. Management must factor operational costs and replacement inflation into pricing models without pricing out the target demographic.
A sustainable DRF requires routine auditing and strict monitoring mechanisms. Regular physical stock counts must reconcile with bin cards and electronic sales records to detect discrepancies, pilferage, or unrecorded waste. Management committees should review financial statements monthly to track the fund's health.
Transparency builds trust among stakeholders, including patients and healthcare workers. When losses occur due to theft or mismanagement, swift accountability measures must follow. Without regular external audits and internal oversight, revolving funds frequently collapse under the weight of corruption and administrative neglect.
While pharmacists manage dispensing windows, nurses play an indispensable frontline role in protecting the DRF. Nurses administer treatments, manage ward stock cupboards, and often serve as the first point of contact for patients reporting drug side effects or shortages.
Nurses ensure rational drug use by adhering strictly to prescription guidelines, preventing wastage in the wards. Furthermore, because nurses interact closely with patients, they can provide honest feedback on drug quality, affordability, and stock availability to the management committee. Integrating clinical nursing perspectives into DRF committees bridges the gap between financial managers and the patients they serve.